Panzyga for Hypogammaglobulinemia

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Hypogammaglobulinemia+5 More
Panzyga - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying how well Panzyga works in preventing primary infection in patients with chronic lymphocytic leukemia.

Eligible Conditions
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia (CLL)

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 52 weeks

52 weeks
Duration of prophylaxis with anti-infectives
Frequency of prophylaxis with anti-infectives
Occurrence of major infections
Overall infection rate

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Panzyga
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

240 Total Participants · 2 Treatment Groups

Primary Treatment: Panzyga · Has Placebo Group · Phase 3

Panzyga
Biological
Experimental Group · 1 Intervention: Panzyga · Intervention Types: Biological
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Human immunoglobulin G
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 52 weeks

Who is running the clinical trial?

OctapharmaLead Sponsor
80 Previous Clinical Trials
7,172 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 18 years of age.
You voluntarily give informed consent before any study-related procedures are conducted.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.